NIPPON EXPRESS HOLDINGS Strengthens Pharmaceutical Logistics Quality System Globally
- Compiles "NX-Pharma Global Quality Manual" and Appoints Head of NX-Pharma Global Quality - TOKYO, March 9, 2023 /PRNewswire/ -- NIPPON EXPRESS HOLDINGS, INC., based in Tokyo, has compiled the NX-Pharma Global Quality Manual, applicable as of Sunday, January 1, 2023, to unify and standardize pharmaceutical logistics quality standards on a global basis. Logo: https://kyodonewsprwire.jp/img/202303013462-O1-7reh962D Image: NX-Pharma Global Quality Manualhttps://kyodonewsprwire.jp/prwfile/release/M103866/202303013462/_prw_PI2fl_yksd5VnD.jpg...
Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier’s Onco-hematology Portfolio
PARIS, March 9, 2023 /PRNewswire/ -- Servier, a global pharmaceutical group, today announced it has entered into a strategic partnership with QIAGEN, a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life, to develop a companion diagnostic test...
GRAND LAUNCHING OF DNATEST.ID, A COMPREHENSIVE DNA TEST IN INDONESIA
JAKARTA, Indonesia, March 9, 2023 /PRNewswire/ -- PT Henindo Technologies Citra Mulia (HENINDO) together with PT Regene Artifisial Inteligen (REGENE) announce the launching of a comprehensive DNA TEST under the brand name of DNAtest.id. The event was attended by Prof. Dr. Amien Soebandrio, PhD, SpMK(K), Indonesian DNA Expert, Prof. Dr. dr. Yudi Ahmad Yudianto, SpFM(K), SH, M.K, Indonesian DNA Expert, ...
DIGITAL THERAPEUTICS STARTUP RESPIREE™ GAINS US FDA CLEARANCE FOR ITS RS001 CARDIO-RESPIRATORY WEARABLE
SINGAPORE, March 9, 2023 /PRNewswire/ -- Digital therapeutics startup Respiree has received the United States Food and Drug Administration's 510(k) clearance for its RS001 cardio-respiratory wearable. Illustrative Image of Respiree™’s RS001 Cardio-respiratory Wearable The RS001 is a chest wearable that measures respiration directly and can be used on patients suffering from cardio-pulmonary...
Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas
Initiation of Phase I/II Clinical Trial (Starlight-1) Expected to Occur in Second Half of 2023 EMERYVILLE, Calif. and NEW YORK, March 9, 2023 /PRNewswire/ -- Estrella Biopharma, Inc. ("Estrella"), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer with safe, effective therapies, and...
Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD)
– CELLEX ECP is now available for reimbursement in Japan for patients who are steroid-resistant or -intolerant and suffering from cGvHD – DUBLIN, March 9, 2023 /PRNewswire/ -- Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Japan's National Health Insurance (NHI) system has...
Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU
MELBOURNE, Australia, March 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company's carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 – 13 March 2023. Further...
ETAO International Entered Into Standby Equity Purchase Agreement of Up To $150 Million with YA II PN, Ltd.
NEW YORK, March 9, 2023 /PRNewswire/ -- ETAO International Co., Ltd. ("ETAO" or the "Company") announced on February 24, 2023, ETAO and YA II PN, Ltd., a Cayman Islands exempt limited partnership (the "Investor") managed by Yorkville Advisors Global, LP (the "Investment Manager"), entered into a Standby Equity Purchase Agreement (the "SEPA"). The Investor is a fund headquartered...
Decipher Fat Burning: A Breath Analyzer Achieved Funding Goal on Indiegogo in 1 Hour
SINGAPORE, March 9, 2023 /PRNewswire/ -- Singapore-based Tech startup Metanoia Sensing has announced a new breath analyzer 'MetaNose' to help people monitor their fat (lipid) burning status. The device also provides insights into the users' metabolic health risk such as diabetic related conditions. The MetaNose device has been launched on Indiegogo and has reached its funding goal within the first...
BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events
CAMBRIDGE, Mass. and DAEJEON, South Korea, March 8, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging its proprietary Brain-Targeting RNAi Nanomedicine (BTRiNTM) technology to combine targeted cell delivery capabilities and proprietary RNA interference (RNAi) chemistries, to develop best-in-category RNAi therapeutics, today announced...
